A phase I open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2879552 given orally in subjects with relapsed/refractory acute myeloid leukemia
The goal of the "rechallenge/restart" part of this clinical research study is to continue to provide GSK2879552 to patients who had liver side effects while they were taking the study drug and needed to stop taking it. This is only being offered because the study doctor thinks, based on your lab results, that it is in your best interest to continue receiving the study drug.
Treatment Location: N/A
IRB Review and Approval Date: 02/28/2017
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: